Trinity Biotech PLC income statement TRIB

Annual Quarterly

In fiscal 2024, which ended Dec 31, 2024, Trinity Biotech PLC reported revenue of $61.6 million, up 8.3% from the year before. It recorded a net loss of $31.2 million. The operating loss came to $21.2 million, an operating margin of -34.4%. Across the 8 fiscal years shown, revenue shrank from $99.1 million in fiscal 2017 to $61.6 million in fiscal 2024, about 6.6% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017
Revenue	62 +8.3%	57 -9.1%	63 -23.0%	81 -20.4%	102 +12.8%	90 -6.8%	97 -2.1%	99
Cost of revenue	40 +7.3%	37 -17.4%	45 -5.1%	48 -10.7%	53 +2.1%	52 -5.9%	56 -2.9%	57
Gross profit	21 +10.2%	19 +12.6%	17 -48.4%	33 -31.1%	49 +27.4%	38 -8.0%	41 -1.1%	42
Research and development	5 +3.7%	4 +5.8%	4 -8.0%	4 -11.5%	5 -4.6%	5 -0.8%	5 -5.1%	6
Selling, general and administrative	29 -7.5%	31 +15.5%	27 +19.9%	23 -14.7%	26 -4.6%	28 -6.2%	29 -8.6%	32
Operating income	-21 +21.7%	-27 -39.8%	-19 -591.3%	4 +4702.4%	0 +100.3%	-24 -19.2%	-20 +46.3%	-38
Finance costs	10 -13.5%	11 -55.3%	25 +249.1%	7 +4.9%	7 +2.6%	7 +29.6%	5 -6.0%	5
Pretax income	-31 +16.8%	-37 +15.7%	-44 -2175.5%	-2 +71.0%	-7 +77.9%	-30 -29.4%	-23 +41.9%	-40
Income tax	0 +923.7%	-0 +69.6%	-0 -162.2%	-0 +88.1%	-1 +38.4%	-1 -91.6%	-1 +56.8%	-1
Net income	-31 +15.3%	-37 +15.4%	-44 -2256.0%	-2 +69.2%	-6 +79.3%	-29 -28.0%	-23 +41.4%	-39
Weighted average shares, basic	359 +134.6%	153 +13.5%	135 +61.4%	84 +0.0%	84 +0.0%	84 -0.0%	84 -3.3%	86
Weighted average shares, diluted	—	—	80 +115.0%	37 -2.0%	38 -62.9%	102 -1.6%	104 -3.7%	108
Other measures
Depreciation and amortization	0	0 -100.0%	38	—	0 +900.0%	0 -94.9%	0 -85.0%	1
EBITDA	-21 +22.5%	-27 -245.0%	19	—	0 +100.5%	-24 -19.7%	-20 +45.8%	-37
Interest coverage	-2.21x	-2.45x	-0.78x	0.56x	0.01x	-3.66x	-3.98x	-6.97x
Margins
Gross margin	34.83%	34.22%	27.62%	41.23%	47.64%	42.15%	42.72%	42.25%
Operating margin	-34.38%	-47.59%	-30.95%	4.85%	0.08%	-26.66%	-20.85%	-37.99%
Pretax margin	-49.92%	-64.98%	-70.02%	-2.37%	-6.50%	-33.17%	-23.89%	-40.22%
Profit margin	-50.71%	-64.87%	-69.71%	-2.28%	-5.90%	-32.06%	-23.35%	-39.00%
EBITDA margin	-34.05%	-47.59%	29.83%	—	0.12%	-26.66%	-20.76%	-37.46%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: TRIB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: Ireland
Headquarters: Wicklow
SEC filer status: Non-accelerated filer
SEC CIK: 888721

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.